Further studies demonstrated that higher expression level of HHLA2 in human lung cancer tissues significantly associated with EGFR mutation, higher intensities of TILs and PD-L1 status, suggesting an effective immunotherapy strategy for PD-L1-negative patients [37, 38]. This evidence concerns the gene EGFR and lung cancer.